Significance: This study provides a novel molecular mechanism by which c-FLIP L cleavage is required for NF-B activation.
and can mediate apoptosis and diverse non-apoptotic functions (1) (2) (3) . The DD is used to recruit adaptor proteins and is essential for the formation of a multiple-protein complex designated death-inducing signaling complex (DISC) (4) . Upon engagement with Fas ligand (FasL), Fas recruits Fas-associated death domain (FADD), which contains a DD and a death effector domain (DED) via homotypic DD interaction in the DISC (5) . Caspase 8 is an initiator caspase that contains two DEDs within its prodomain in addition to large and small protease subunits that facilitate recruitment to FADD (6, 7) . Caspase 8 then undergoes dimerization and proteolytic cleavage, leading to the generation of active heterotetramers consisting of the large and small subunits (8) .
In response to death receptor ligation, caspase 8 plays an essential role in the regulation of apoptotic and non-apoptotic signaling pathways (9 -11) . To transmit apoptotic signals, active caspase 8 cleaves various substrates, such as caspase 3 and the Bcl-2 family protein Bid, into active forms (9 -11) . Caspase 8 also plays an essential role in the regulation of another form of cell death referred to as programmed necrosis (12) . Serine/threonine protein kinase-designated receptor-interacting protein 1 (RIP1) and RIP3 are essential for the induction of programmed necrosis (13) (14) (15) . It has been shown that RIP1 and RIP3 mediate the embryonic lethality of caspase 8-and FADD-deficient mice via the induction of necrosis (16 -18) . In addition to cell death pathways, it has been shown that, * This work was supported by Grants-in-aid for Scientific Research (KAKENHI) in response to Fas or antigen receptors, caspase 8 can trigger the activation of the transcription factor nuclear factor B (NF-B) that drives many target genes, including antiapoptotic proteins (19 -22) .
Cellular FLICE-inhibitory protein (c-FLIP) is a crucial modulator of caspase 8, existing in the various splicing forms c-FLIP L , c-FLIP S , and c-FLIP R (23, 24) . The full-length c-FLIP L shows overall homology to caspase 8 and contains two N-terminal DEDs followed by the protease domain that lacks the catalytic cysteine, whereas c-FLIP S and c-FLIP R contain only two DEDs and a short C-terminal tail (25, 26) . Upon heterodimerization with caspase 8 in the DISC, c-FLIP L is processed at Asp-376 into an N-terminal p43 fragment designated c-FLIP(p43) and modulates caspase 8 catalytic activity (27, 28) . c-FLIP is known to play a regulatory role in the apoptotic and non-apoptotic signaling pathways (25, 26, 29 -31) . c-FLIP L inhibits death receptor-mediated apoptosis by preventing the homodimerization of caspase 8 in the DISC, but it can also exert proapoptotic activity under limited conditions (32) . c-FLIP possesses the ability to induce the activation of the NF-B signaling pathway (33) (34) (35) (36) (37) (38) (39) , and we have shown previously that c-FLIP(p43) is able to induce NF-B activation by interaction with TNF receptor-associated factor 2 (TRAF2) (36) . c-FLIP(p22), another c-FLIP fragment cleaved by caspase 8 at Asp-196, has also been shown to mediate NF-B activation by binding to the inhibitor of NF-B (IB) kinase complex (38) . By contrast, it has been shown that c-FLIP L and c-FLIP S inhibit NF-B activation induced by FasL (19, 20, 40) . These seemingly contradictory findings may be explained partly by the notion that c-FLIP L and its isoforms can promote or inhibit Fas-mediated NF-B activation, depending on their expression levels and cellular context (39) .
RIP1 is known to be critical to induce NF-B activation in response to death receptors and other stimuli (41, 42) . We have shown that caspase 8 promotes the interaction between RIP1 and c-FLIP(p43) (37) . It has also been demonstrated that c-FLIP(p43) interacts with the IB kinase complex upon Fas stimulation (39) . Thus, in addition to the specific interaction between c-FLIP(p43) and TRAF2 (36) , these studies collectively indicate the importance of c-FLIP L processing in the activation of the NF-B signaling pathway. In this study, we have further explored the molecular mechanism by which c-FLIP L processing regulates NF-B activation. Our results demonstrate that the C-terminal domain of c-FLIP L inhibits the interaction between the caspase 8 prodomain and the RIP1 DD and, thereby, regulates caspase 8-dependent NF-B activation.
EXPERIMENTAL PROCEDURES
Cells-HEK293 cells (JCRB9068) were provided by the Health Science Research Resources Bank (Osaka, Japan). HEK293 cells and HEK293C8L cells (HEK293 cells expressing caspase 8 at very low levels) (36, 43) were maintained in DMEM (Invitrogen) supplemented with 10% (v/v) heat-inactivated FCS (Nichirei Biosciences, Tokyo, Japan) and penicillin/streptomycin mixed solution (Nacalai Tesque, Kyoto, Japan).
Antibodies-Antibodies to ␤-actin (AC-15, Sigma-Aldrich, St. Louis, MO), human caspase 8 (5D3 and 5F7, Medical & Biological Laboratories, Nagoya, Japan), FADD (clone 1, BD Biosciences), Fas (B-10, Santa Cruz Biotechnology, Santa Cruz, CA), FLAG (M2, Sigma-Aldrich), c-FLIP (Dave-2, Alexis, Lausen, Switzerland), RIP1 (clone 38, BD Biosciences, and H-207, Santa Cruz Biotechnology), TNF receptor 1 (H-5, Santa Cruz Biotechnology), TNF receptor 1-associated death domain protein (TRADD) (C-20, Santa Cruz Biotechnology), TRAF2 (C-20, Santa Cruz Biotechnology), and vesicular stomatitis virus (VSV) (P5D4, Sigma-Aldrich) were obtained commercially.
Reagents-Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk) was purchased from the Peptide Institute (Osaka, Japan). Recombinant human TNF-␣ was provided by Dainippon Pharmaceutical (Osaka, Japan). FLAGtagged human soluble FasL (139 -281) was produced in culture supernatants of HEK293T cells and concentrated by Ultracell-10K (Merck Millipore, Darmstadt, Germany). FLAG-tagged FasL was further purified with agarose beads conjugated to anti-FLAG antibody M2 (Sigma-Aldrich). FLAG-tagged FasL in a purified form or concentrated supernatants by ultrafiltration were cross-linked with anti-FLAG antibody (M2, 0.5 g/ml) and used for experiments.
Expression Vectors-pCR3 expression vectors containing either a FLAG tag or VSV tag for human c-FLIP L , human c-FLIP(p43), human c-FLIP S , human c-FLIP L (D376A), human caspase 8, caspase 8(p43), mouse catalytically inactive caspase 8(C362G), and human RIP1 have been described previously (36) . Human caspase 8 deletion mutants (1-178, 1-216, 217-374, 217-479, 375-479, and 385-479), human caspase 8(C360S), and human RIP1 deletion mutants (1-324, 325-671, 1-558, 325-558, and 559 -671) were generated by PCR amplification and subcloned into pCR3-based expression vectors containing a FLAG tag or VSV tag. The human DED family of proteins was generated by PCR amplification using cDNA libraries prepared from human cancer cell lines (A549 cells for DED-containing DNA-binding protein 2 (DEDD2), phosphoprotein enriched in astrocytes 15 kDa (PEA-15), and BAP31; U937 cells for huntingtin interacting protein 1 (HIP1) and HIP1 protein interactor (HIPPI); and HeLa cells for bifunctional apoptosis regulator (BAR)). DED proteins were subcloned into a pCR3-based expression vector containing a FLAG tag.
Assay for Apoptosis-Cells were stained with Hoechst 33342 (10 M, Merck Millipore) for the last 30 min of incubation. The stained cells were washed with PBS and observed for nuclear morphology under a fluorescence light microscope (Axiovert 200 M, Carl Zeiss, Jena, Germany). Apoptosis (percent) was calculated as (condensed nuclei / total nuclei) ϫ 100.
Reporter Assay-Cells were seeded in 24-well culture plates the day before transfection. The cells were transfected with various expression vectors together with reporter vectors encoding an NF-B-responsive firefly luciferase gene (80 -300 ng/well), a CMV promoter-driven Renilla luciferase gene (20 -100 ng/well), or a ␤-galactosidase gene (200 -400 ng/well) by calcium phosphate method or Lipofectamine TM 2000 (Invitrogen). The NF-B-responsive firefly luciferase gene was controlled by two copies of B sequences from the Ig enhancer (37) . The transfected cells were solubilized in digitonin lysis buffer (10 mM Hepes-KOH (pH 7.2), 100 M digitonin, 250 mM sucrose, 50 mM NaCl, 2 mM MgCl 2 , 5 mM EGTA, and 1 mM DTT) and centrifuged (15,000 ϫ g, 5 min) to sediment insoluble materials. Aliquots of supernatants were mixed with either firefly luciferase assay solution (25 mM Tris-phosphate (pH 7.8), 10 mM MgCl 2 , 15% glycerol, 1% Triton X-100, 1% bovine serum albumin, 0.25 mM luciferin, 1 mM ATP, and 1 mM DTT) or Renilla luciferase assay solution (100 mM potassium phosphate (pH 7.5), 500 mM NaCl, 1 mM EDTA, and 24 M coelenterazine). Relative light units were immediately measured with a Lumitester K-100 luminometer (Hamamatsu Photonics, Hamamatsu, Japan). ␤-Galactosidase activity was determined by incubation of aliquots of supernatants with Z buffer (100 mM sodium phosphate (pH 7.5), 10 mM KCl, 1 mM MgSO 4 , and 40 mM 2-mercaptoethanol) containing 2.2 mM o-nitrophenyl-␤-Dgalactopyranoside at 37°C until a yellow color developed. Absorbance at 415 nm was measured with a Model 680 microplate reader (Bio-Rad). Values of Renilla luciferase activity and ␤-galactosidase activity were used to normalize transfection efficiency.
Immunoprecipitation-Cells were seeded in 60-mm culture dishes the day before transfection. The cells were transfected with various expression vectors, including FLAGtagged expression vectors (total 2 to 4 g DNA), by the calcium phosphate method. The cells were harvested, washed with PBS, and solubilized in Nonidet P-40 lysis buffer (20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 10% glycerol, and 2 mM sodium vanadate) containing the protease inhibitor mixture Complete TM (Roche Diagnostics). After repeated centrifugation (15,000 ϫ g, 5 min), postnuclear lysates were precleared with Sepharose 6B (Sigma-Aldrich) for 1 h and then immunoprecipitated with anti-FLAG M2 affinity gel (Sigma-Aldrich) for 3 h. The affinity gel was washed several times with Nonidet P-40 lysis buffer.
Western Blotting-Cells were washed with PBS and solubilized in Triton X-100 lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Triton X-100, and 2 mM dithiothreitol) containing the protease inhibitor mixture Complete TM (Roche Diagnostics). Postnuclear lysates were collected as supernatants by centrifugation (15,000 ϫ g, 5 min). Protein samples (30 g/lane) were separated by SDS-PAGE and transferred onto Hybond-ECL nitrocellulose membranes (GE Healthcare). The membranes were incubated with primary antibodies and then with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Blots of either ␤-actin or equally transfected proteins for immunoprecipitation were used for loading controls. Protein bands were developed by ECL Western blotting detection reagent (GE Healthcare) and detected by exposure to Hyperfilm TM ECL (GE Healthcare) or ImageQuant LAS 4000 Mini (GE Healthcare). ImageQuant LAS 4000 Mini was used to quantify the intensity of the bands.
Statistical Analysis-Statistical significance was assessed by one-way analysis of variance followed by the Tukey's test for multiple comparisons. Differences of p Ͻ 0.05 were considered to be statistically significant.
RESULTS

Caspase 8 Is Required for FasL-induced NF-B Activation-
HEK293 cells expressed Fas and TNF-R1 as well as caspase 8, FADD, TNF receptor 1-associated death domain protein, RIP1, and TRAF2, whereas HEK293C8L cells expressed caspase 8 at very low levels while expressing the other proteins at levels similar to HEK293 cells (Fig. 1A) . c-FLIP L and c-FLIP S were only weakly expressed in HEK293 and HEK293C8L cells (Fig.  1B and data not shown). Upon FasL stimulation, ϳ35% of HEK293 cells underwent apoptosis within 6 h, whereas HEK293C8L cells did not (Fig. 1C) . In HEK293C8L cells, apoptosis was increased in response to FasL stimulation when wildtype caspase 8, but not catalytically inactive caspase 8, was transiently expressed (Fig. 1D ). NF-B activation was induced by FasL stimulation in HEK293 cells at levels several times lower than TNF-␣ stimulation (Fig. 1E) . In HEK293C8L cells, FasL was unable to induce NF-B activation (Fig. 1E ). When catalytically inactive caspase 8 was transiently expressed in HEK293C8L cells, NF-B activation was induced by FasL ( (Fig. 2C ). This is consistent with our previous observation with HEK293T cells that expressed much higher amounts of protein products (36) . To examine the effect of c-FLIP L processing on NF-B activation induced by FasL, HEK293 cells were transiently transfected with c-FLIP L or c-FLIP(p43) and then stimulated with FasL in the presence or absence of zVAD-fmk. In mocktransfected HEK293 cells, zVAD-fmk did not obviously affect FasL-induced NF-B activation (Fig. 2D ). However, interestingly, zVAD-fmk markedly inhibited FasL-induced NF-B activation in HEK293 cells transiently transfected with c-FLIP L (Fig. 2D) . By contrast, FasL-induced NF-B activation was relatively insensitive to zVAD-fmk in c-FLIP(p43)-transfected cells (Fig. 2D) . In mock-transfected HEK293 cells, FasL stimulation induced the cleavage of caspase 8 from p55/p53 into p43/ p41 and p18 (Fig. 2, E-G) . In HEK293 cells transfected with c-FLIP L , FasL stimulation increased the cleavage of c-FLIP L into c-FLIP(p43) (Fig. 2E) . zVAD-fmk efficiently inhibited the processing of c-FLIP L and caspase 8 (Fig. 2, E-G) . By contrast, the FasL-induced cleavage of caspase 8 into its p43/p41 and p18 fragments was not decreased by expression of c-FLIP L or c-FLIP(p43) (Fig. 2, E-G) . This might be due to the fact that the dose of FasL was high and overcame the effect of c-FLIP L or c-FLIP(p43) or that the time point was sufficiently long after FasL stimulation to allow substantial caspase 8 cleavage to proceed even with c-FLIP L or c-FLIP(p43). It might be also possible that c-FLIP L or c-FLIP(p43) was expressed between the levels that promote or inhibit the processing of caspase 8 because it
c-FLIP L Inhibits Interaction between Caspase 8 and RIP1
has been shown that c-FLIP L can act as both an activator and an inhibitor of caspase 8 (44 -46) . Overall, these results suggest that augmented NF-B activation by c-FLIP L , but not c-FLIP(p43), requires caspase activity in HEK293 cells.
Caspase 8 Interacts with the RIP1 DD-RIP1 is composed of a kinase domain, an intermediate domain, a RIP homotypic interaction motif, and a C-terminal DD (Fig. 3A) . RIP1(559 -671) contains only a DD and serves as a dominant-negative form that blocks RIP1-mediated NF-B activation. In our previous study, caspase 8 was found to interact with endogenous RIP1 but not TRAF2 (36, 37) . To identify the RIP1 region responsible for interacting with caspase 8, FLAG-tagged RIP1 deletion mutants were transiently coexpressed with caspase 8 or its cleaved form caspase 8(p43) in HEK293C8L cells. Caspase 8 was immunoprecipitated with RIP1(1-671), RIP1(325-671), RIP1(559 -671), and, to a lesser extent, with RIP1(1-558) but not at all with RIP1(1-324) and RIP1(325-558) (Fig. 3B) . Similar results were observed with caspase 8(p43), except that it did not interact with RIP1(1-558) (Fig. 3C ). RIP1(559 -671) was immunoprecipitated with caspase 8 as well as caspase 8(p43) with similar efficacy (Fig. 3D) . These results indicate that the RIP1 DD is essential for the interaction with caspase 8. This notion was also supported by the observation that caspase 8 pulled down RIP1 but not other RIP family members that lack a DD (i.e. RIP2, RIP3, and RIP4) (Fig. 3E) .
The Caspase 8 Prodomain Interacts with the RIP1 DDCaspase 8 is composed of two DEDs and a caspase domain consisting of large (p18) and small (p10) subunits (Fig. 4A) . To identify the region of caspase 8 responsible for the interaction with RIP1(559 -671), RIP1(559 -671) was transiently coexpressed with FLAG-tagged caspase 8 deletion mutants in HEK293C8L cells (Fig. 4B) . RIP1(559 -671) was immunoprecipitated with caspase 8, caspase 8(p43), caspase 8(1-216), and caspase 8(1-178) but not caspase 8(217-479), caspase 8(217-374), caspase 8(375-479), and caspase 8(385-479) (Fig. 4B) . These data indicate that the caspase 8 prodomain that contains two DEDs is sufficient for the interaction with the RIP1 DD. In addition to caspase 8, RIP1(559 -67) was able to interact with FADD and caspase 10 but not other DED family proteins (i.e. c-FLIP L , DEDD2, PEA-15, BAP31, HIP1, HIPPI, and SSC2) (Fig. 4C) . to induce NF-B activation compared with caspase 8 and caspase 8(p43) (Fig. 5A and data not shown) . By contrast, neither caspase 8(217-374), caspase 8(217-479), or caspase 8(375-479), nor caspase 8(385-479), induced NF-B activation in HEK293C8L cells (Fig. 5A) . FasL was able to induce NF-B activation in HEK293C8L cells transfected with caspase 8(1-178) (Fig. 5B) . These data indicate that the caspase 8 prodomain is sufficient to mediate FasL-induced NF-B activation.
The Caspase 8 Prodomain Is Sufficient to Induce NF-B Activation by FasL or c-FLIP(p43)-NF-B
c-FLIP(p43) was able to induce NF-B activation in HEK293C8L cells when catalytically inactive caspase 8 was coexpressed (Ref. 36 and data not shown). In addition to fulllength caspase 8, c-FLIP(p43) was found to induce NF-B activation markedly when HEK293C8L cells were cotransfected with caspase 8(1-178) and caspase 8(1-216) (Fig. 5, C and D) . NF-B activation induced by c-FLIP(p43) plus caspase 8(1-178) or caspase 8(1-216) was inhibited by RIP1(559 -671) (Fig.  5, E and F) . Thus, these data indicate that the caspase 8 prodomain is sufficient to mediate c-FLIP(p43)-induced NF-B activation in a RIP1-dependent manner. (Fig. 6A) . The interaction of RIP1(559 -671) with caspase 8 was decreased markedly when c-FLIP L was coexpressed (Fig. 6A) . By contrast, c-FLIP(p43) allowed the interaction between caspase 8 and RIP1(559 -671) (Fig. 6A) . Thus, these data indicate that the C-terminal region of c-FLIP L inhibits the interaction between the RIP1 DD and caspase 8.
In HEK293 cells, cFLIP L , or its uncleavable form, c-FLIP L (D376A), induced spontaneous NF-B activation that was only weakly inhibited by RIP1(559 -671) (Fig. 6, B and C) . In addition, FasL was able to induce NF-B activation in the presence of c-FLIP L but exerted weaker NF-B activation in the presence of c-FLIP L (D376A) (Fig. 6, B and C) . FasL-induced NF-B activation in the presence of c-FLIP L , but not c-FLIP L (D376A), was inhibited by RIP1(559 -671) (Fig. 6C) . RIP1(559 -671) also strongly blocked FasL-induced and spontaneous NF-B activation in the presence of c-FLIP(p43) (Fig.  6C) . These results support the view that c-FLIP L regulates a RIP1-dependent and a RIP1-independent pathway to NF-B activation, whereas c-FLIP(p43) regulates only a RIP1-dependent pathway, and c-FLIP L (D376A) regulates only a RIP1-independent pathway. Overall, these findings are consistent with a model in which caspase 8 activity is necessary to cleave c-FLIP L to c-FLIP(p43) to promote a RIP1-dependent pathway of NF-B activation, which may be the main c-FLIP pathway at normal physiological levels. Caspase 8 is essential to induce NF-B activation in response to FasL stimulation (19, 20) . By contrast, c-FLIP L and c-FLIP S have been reported to inhibit FasL-induced NF-B activation (19, 20, 40) . Recently, it has been shown that subtle differences in concentrations of c-FLIP isoforms determine apoptosis induction as well as NF-B activation in the Fas signaling pathway (32, 39) . Thus, it is mostly likely that c-FLIP isoforms are able to regulate FasL-induced NF-B activation positively or negatively under various cellular conditions. Even though the amount of c-FLIP isoforms is much smaller than that of caspase 8, they are efficiently recruited to the DISC because of their higher affinity to the DISC compared with caspase 8 (47) . FEBRUARY 14, 2014 • VOLUME 289 • NUMBER 7 Fas-DISC. Nevertheless, it has been shown that c-FLIP L does not inhibit caspase 8 recruitment but, rather, promotes the formation of the caspase 8(p43)⅐c-FLIP(p43) heterodimers in the Fas-DISC (32, 35) . Moreover, c-FLIP L was found to increase the recruitment of RIP1 and TRAF2 to the Fas DISC (35) . Thus, c-FLIP L is most likely to mediate NF-B activation in response to FasL stimulation only when c-FLIP L does not inhibit the recruitment of caspase 8 to the Fas DISC but inhibits the full activation of caspase 8, which leads to the formation of the active heterotetramer.
DISCUSSION
c-FLIP L Inhibits Interaction between Caspase 8 and RIP1
We have shown that FasL-induced NF-B activation is regulated by c-FLIP L at the step of caspase 8-dependent cleavage in the DISC. c-FLIP L is processed by caspase 8 into N-terminal c-FLIP(p43) and C-terminal c-FLIP(p12) in the DISC. The caspase 8 complex associated with either c-FLIP L or c-FLIP(p43) exerts enzymatic activity (27, 28) . It has been shown recently that the enzymatic activity of the caspase 8⅐c-FLIP complex inhibits RIP1/RIP3-dependent necrosis (17) . By contrast, the enzymatic activity of the caspase 8⅐c-FLIP(p43) complex is dispensable for FasL-induced NF-B activation because zVAD-fmk did not inhibit FasL-induced NF-B activation in the presence of c-FLIP(p43). However, zVAD-fmk markedly inhibited NF-B activation induced by FasL stimulation only in the presence of c-FLIP L . Consistent with these results, it has been shown previously that zVAD-fmk inhibits caspase 8-dependent NF-B activation induced by overexpression of c-FLIP L (34, 36, 38) . These studies indicate that c-FLIP L processing to c-FLIP(p43) by caspase 8 is indispensable for FasL-induced NF-B activation. In response to FasL stimulation, it is possible that caspase inhibitors such as zVAD-fmk promote NF-B activation by suppressing caspase 8-dependent apoptosis in Fas-susceptible cells expressing no c-FLIP isoforms. However, as shown in this paper, caspase inhibitors are also likely to block NF-B activation by suppressing the cleavage of c-FLIP L into c-FLIP(p43) in Fas-resistant cells expressing a sufficient amount of c-FLIP L .
As discussed above, caspase 8 activity is required for c-FLIP L cleavage into c-FLIP(p43) but not for downstream molecular events in the FasL-induced NF-B signaling pathway. We showed previously that c-FLIP(p43), but not c-FLIP L , specifically interacts with TRAF2 (36) . It has also been reported that c-FLIP(p43) interacts with the IB kinase complex upon Fas stimulation (39) . These studies collectively underscore the importance of c-FLIP L cleavage for FasL-induced NF-B activation. Upon TNF-␣ stimulation, TNF receptor 1 recruits TNF receptor 1-associated death domain protein, which binds TRAF2 and RIP1, and in the membrane-associated complex both proteins undergo polyubiquitination, which recruits and activates the TGF-␤-activated kinase (TAK1) complex and the IB kinase complex (49) . In agreement with this study, it has been shown that RIP1 plays an essential role in FasL-induced NF-B activation (20) . However, in contrast with TNF receptor 1, the caspase 8⅐c-FLIP(p43) heterodimers might be used as a RIP1 interacts with multiple proteins, including death receptors, adaptor proteins, and caspases (41, 42) . Consistent with previous studies (33, 50, 51) , we have shown that RIP1 interacts with caspase 8. However, partly different from these studies (33, 50), we have found that the RIP1 DD is responsible for interaction with the caspase 8 prodomain. Other RIP family members that did not contain a DD (including RIP3) were not immunoprecipitated with caspase 8. In addition, the RIP1 DD was immunoprecipitated with caspase 8 but not c-FLIP L . Unlike transfected RIP1, which has been shown to interact with the c-FLIP L in HEK293T cells overexpressing both proteins (33), endogenous RIP1 was immunoprecipitated efficiently with 
caspase 8 and caspase 8(p43) but not c-FLIP L . Thus, it is most likely that RIP1 primarily binds caspase 8 via the DD-DED interaction in the caspase 8⅐c-FLIP(p43) heterodimers.
Ripoptosome is a large, 2-MDa intracellular complex that contains RIP1, FADD, caspase 8, caspase 10, and c-FLIP isoforms and regulates the cell death decision between caspasedependent apoptosis and RIP1-dependent necrosis (52, 53) . In the absence of cellular inhibitor of apoptosis proteins (c-IAPs), c-FLIP L inhibits the formation of Ripoptosome and blocks apoptosis and necrosis, whereas c-FLIP S promotes Ripoptosome formation and necrosis (52) . The interaction of RIP1 with caspase 8 in the Ripoptosome is decreased by c-FLIP L but increased by c-FLIP S (52) . This is in line with this study showing that the C-terminal domain of c-FLIP L inhibits the binding of RIP1-DD to caspase 8. However, in contrast to c-FLIP L being cleaved efficiently to c-FLIP(p43) by caspase 8 in the Fas-DISC, it is possible that the caspase 8⅐c-FLIP L heterodimer is not efficiently converted to the caspase 8⅐c-FLIP(p43) heterodimer in the Ripoptosome and that the caspase 8⅐c-FLIP L heterodimer is most likely to either interfere with RIP1 recruitment or mediate RIP1 cleavage and, thereby, prevent RIP1/RIP3-dependent necrosis.
Overexpression of c-FLIP L or its uncleavable form, c-FLIP L (D376A), induced spontaneous NF-B activation that was not inhibited by RIP1(559 -671). By contrast, FasL-induced NF-B activation in the presence of c-FLIP L or c-FLIP(p43) was inhibited by RIP1(559 -671). Thus, it is possible that c-FLIP L regulates a RIP1-dependent as well as a RIP1-independent NF-B pathway, whereas c-FLIP(p43) regulates only a RIP1-dependent NF-B pathway, and c-FLIP(D376A) regulates only a RIP1-independent NF-B pathway. We have reported previously that a dominant-negative TRAF2 inhibits NF-B activation induced by c-FLIP(p43) but not that induced by c-FLIP L (D376A) (36) . Moreover, we have shown that TRAF2 interacts specifically with c-FLIP(p43) but not c-FLIP L (36) . Thus, it is most likely that c-FLIP(p43) mediates NF-B activation in a TRAF2/RIP1-dependent manner, whereas c-FLIP(D376A) mediates NF-B activation in a TRAF2/RIP1-independent manner. The molecular mechanism of the NF-B signaling pathway induced by c-FLIP L (D376A) remains to be clarified.
How does c-FLIP L or c-FLIP(p43) regulate the interaction of caspase-8 and RIP1? In this study, we have shown that the C-terminal domain of c-FLIP L inhibits the interaction between caspase 8 and the RIP1 DD. We propose a working model for NF-B activation regulated by caspase 8 and c-FLIP L (Fig. 7) . When c-FLIP isoforms are not sufficiently expressed, caspase 8 undergoes homodimerization and autoprocessing in response to FasL stimulation, leading to the formation of active heterotetramers and the induction of apoptosis. In the presence of c-FLIP L , caspase 8 is able to heterodimerize predominantly with c-FLIP L in the Fas-DISC and, subsequently, cleaves c-FLIP L at Asp-376 to produce N-terminal c-FLIP(p43) and C-terminal c-FLIP(p12). The C-terminal domain of c-FLIP L has an ability to inhibit the interaction between the caspase 8 DED and RIP1 DD by a currently unknown mechanism. The removal of c-FLIP(p12) allows caspase 8 to interact with RIP1. In addition, TRAF2 is specifically interacted with c-FLIP(p43) (36) . The caspase 8⅐c-FLIP(p43) heterodimer subsequently promotes NF-B activation via RIP1 and TRAF2 in a catalytic FEBRUARY 14, 2014 • VOLUME 289 • NUMBER 7 activity-independent manner. It has been proposed that the caspase 8⅐c-FLIP L heterodimer inhibits RIP1/RIP3 activity to prevent necrosis in a catalytic activity-dependent manner (54) . In several cell lines, the full-length RIP1 was detectable in the Fas DISC and associated with the caspase 8⅐c-FLIP(p43) complex (35, 37, 51) . Therefore, it is possible that RIP1 is not necessarily cleaved in the Fas DISC and plays an essential role in the promotion of NF-B activation within the caspase 8⅐c-FLIP(p43) complex.
In conclusion, we have shown that the C-terminal domain of c-FLIP L blocks FasL-induced NF-B activation by inhibiting the interaction between RIP1 and caspase 8. Thus far, it is well known that c-FLIP L modulates the recruitment of caspase 8 to the DISC as well as the catalytic activity of caspase 8 by heterodimerization. Our current findings provide a novel molecular mechanism by which the caspase 8-dependent c-FLIP L cleavage regulates FasL-induced NF-B activation and may partly explain previously controversial studies on a physiological role of c-FLIP L for FasL-induced NF-B activation.
